Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0363-5023(82)80101-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.
Blood
January 2025
Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven patients (17.
View Article and Find Full Text PDFInequalities and Inclusion in Genomics Applied to Healthcare: A Latin American Perspective.
Annu Rev Genomics Hum Genet
January 2025
1Department of Medical Genetics and Genomic Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil;
Integrating genomics into healthcare within the precision medicine (PM) framework poses distinct challenges in resource-limited regions like Latin America and the Caribbean (LAC). These challenges arise partly from the lack of PM models tailored for low- and middle-income countries. To address this, healthcare authorities in LAC should adopt predictive models to estimate costs and infrastructure needed for PM programs.
View Article and Find Full Text PDFEstimating the trend of COVID-19 in Norway by combining multiple surveillance indicators.
PLoS One
January 2025
Norwegian Institute of Public Health, Division of Infection Control, Oslo, Norway.
Estimating the trend of new infections was crucial for monitoring risk and for evaluating strategies and interventions during the COVID-19 pandemic. The pandemic revealed the utility of new data sources and highlighted challenges in interpreting surveillance indicators when changes in disease severity, testing practices or reporting occur. Our study aims to estimate the underlying trend in new COVID-19 infections by combining estimates of growth rates from all available surveillance indicators in Norway.
View Article and Find Full Text PDFObesity phenotypes and dyslipidemia in adults from four African countries: An H3Africa AWI-Gen study.
PLoS One
January 2025
Faculty of Health Sciences, Sydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand, Johannesburg, Johannesburg.
Introduction: The contribution of obesity phenotypes to dyslipidaemia in middle-aged adults from four sub-Saharan African (SSA) countries at different stages of the epidemiological transition has not been reported. We characterized lipid levels and investigated their relation with the growing burden of obesity in SSA countries.
Methods: A cross-sectional study was conducted in Burkina Faso, Ghana, Kenya and South Africa.
Fast and accurate imputation of genotypes from noisy low-coverage sequencing data in bi-parental populations.
PLoS One
January 2025
DIADE, IRD, Cirad, University of Montpellier, Montpellier, France.
Motivation: Genotyping of bi-parental populations can be performed with low-coverage next-generation sequencing (LC-NGS). This allows the creation of highly saturated genetic maps at reasonable cost, precisely localized recombination breakpoints (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!